<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cellectar-BioSciences-Inc-US15117F3029">Cellectar BioSciences, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3287522/29076/en/Cellectar-Biosciences-Reports-Positive-12-Month-Follow-Up-Data-from-Phase-2b-CLOVER-WaM-Study-Demonstrating-Durable-Responses-and-Efficacy-of-Iopofosine-I-131-in-r-r-Waldenstr%C3%B6m-Ma.html">Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia</a>
    </div>

      <div class="me-0 me-md-5">
        83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26 Compelling efficacy observed in post-BTKi patients, including ~64% MRR and durable responses exceeding 18 ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Cellectar-BioSciences-Inc-US15117F3029">Cellectar BioSciences, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/05/3287496/29076/en/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million.html">Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million</a>
    </div>

      <div class="me-0 me-md-5">
        Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along with Members of the Executive Management Team Financing of up to $140 Million Supports Confirmatory...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Cellectar-BioSciences-Inc-US15117F3029/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>